AGENDA

Enclosure

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission (WPAS)
Levofloxacin (Quinsair®) for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis

6. Appraisal 2: Instructed Appraisal (WPAS)
Sofosbuvir/velpatasvir (Epclusa®) for the treatment of chronic hepatitis C virus (HCV) infection in adults

The meeting will now open to the public (approximately 11.00am)

7. Chairman’s report (verbal update)

8. Vitamins for Babies, Children and Pregnant and Breastfeeding Women

9. Review of existing advice:
Insulin detemir (Levemir®) for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

10. Appraisal 3: Full Submission
Aviptadil/phentolamine (Invicorp®) for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology

12. **Monitoring Usage in Wales of Medicines Appraised by NICE and AWMSG – Data to March 2016**

13. **Appraisal 4: Limited Submission**
   Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®) for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL

14. **Appraisal 5: Full Submission**
   Dequalinium chloride (Fluomizin®) for the treatment of bacterial vaginosis

15. **Feedback from AWPAG Meeting held 28th September 2016**